国际合作是加速我国创新药研发的助推器——南京先声药业集团国际合作成果调研

中国是世界第三大药品市场，但新药研发能力低下，70％是仿制药，具有完全自主知识产权的创新药风毛麟角。南京先声药业集团积极开辰国际合作，吸引了大批海外高端人才，极大提升了研发能力，并成功开拓多种渠道获职新药，对促进我国新药研发模式进行了有益的探索。对先声药业集团国际合作＋持续投入研发＋顶尖开发团队的发展战略和实践经验进行介绍，其典型意义在于：世界医药行业正处在一种求变的局势中，各个方面都有着可待开发的机遇；中国药企应大力开展国际合作，主动逐步融入全球健康产业链，成为其中不可缺少的中坚力量；抓住中国的国际机会，在国际合作中获得国内定价权。

International Cooperation is the Booster to Accelerate the Innovative Drug R & D in China

China is the world＇s third-largest pharmaceutical market, but its new drug research and development ability is low. The 70 percent of annual new drugs is generic drugs, while new drugs with independent intellectual property rights are very rare. Nanjing Simcere Pharmaceutical Group has been exploring the efficient model for the new drug R＆D and paved several channels to create new drugs through international cooperation. This paper introduces Simcere Group＇s development strategy and practice experience, i.e., through international cooperation, improve the ability of the drug development and attract foreign high-end talents. The Chinese pharmaceutical enterprises should enter the global health industry chains to become an indispensible branch via international cooperation, in the meantime try to seize the opportunity to get the pricing power in the domestic market.